Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Evans MF, Poulos C, Smith VK. Who counts in evaluating the effects of air pollution policies on households? Non-market valuation in the presence of dependencies. J Environ Econ Manage. 2011 Jul 1;62(1):65-79.
Smith VK, Mansfield CA. Buying time: real and hypothetical offers. J Environ Econ Manage. 1998;36(3):209-24.